Management of deep vein thrombosis in cancer patients

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue SUPPL. 1, 2005, Pages

  Jahanzeb, Mohammed ^a,b  

^a University of Tennessee Cancer Institute ^*

^b UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

Author keywords

Carcinoma; Deep vein thrombosis; Low molecular weight heparin; Unfractionated heparin; Warfarin

Indexed keywords

DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT;

BLEEDING; CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; ARTICLE; NEOPLASM; VEIN THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; VENOUS THROMBOSIS; WARFARIN;

EID: 33644838875     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Johnson MJ, Walker ID, Sproule MW, Conkie J. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 1999;21:51-54.
2. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine 1999;78:285-291.
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722.
4. Hettiarachchi RJ, Prins MH, Lensing AW, Buller HR. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med 1998;4:220-225.
5. Gould MK, Dembitzer AD, Doyle RL, et al. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809.
6. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:677-681.
7. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996;334:682-687.
8. The Columbus Group. Low molecular weight heparin in the treatment of patient with venous thromboembolism. N Engl J Med 1997;337:657-662.
9. Merli G, Spiro TE, Olsson CG. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202.
10. Prandoni P, Lensing AW, Piccioli, A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;1000:3484-3488.
11. Hutton BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a prospective study. J Clin Oncol 2000;18:3078-3083.
12. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662.
13. Deitcher SR, Kessler CM, et al. Secondary prevention of venous thromboembolic events (VTE) in patients with a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium following a 180-day period. J Thromb Haemost 2003; 1 Supplement 1 July: Abstract number OC194.
14. Hull R, Pineo GF, Mah AF, et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for intravenous heparin followed by warfarin sodium in patients with current cancer. J Thromb Haemost 2003; 1 Supplement 1 July: Abstract number P1273a.
15. Lee AY, Levine MN, Baker RI, et al. Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
16. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-952.
17. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):401S-428S.
18. Fiessinger JH, Huisman MV, Davidson BL, et al. Ximelagatran vs. low molecular weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 2005;293:736-739.
19. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patient with proximal deep vein thrombosis. N Engl J Med 1998;338:409-415.